Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P495: Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survivalECCO '17 Barcelona
Year: 2017
Authors:

Al Khoury A.*1, Chao C.-y.2, Aruljothy A.2, Wyse J.3, Bessissow T.2

1McGill University, Gastroenterology, Montreal, Canada 2McGill University Health Centre, Department of Gastroenterology, Montréal, Canada 3Jewish General Hospital, Department of Gastroentelrology, Montréal, Canada

P496: Successful dose de-escalation to adalimumab 40mg every three weeks in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Ferrante M.*1, Van Steenbergen S.1, Bian S.2, Ballet V.1, Vermeire S.1, Van Assche G.1, Gils A.2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 2KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium

P497: Impacts of mucosal healing on clinical outcomes in patients with refractory ulcerative colitis on tacrolimus or biologicsECCO '17 Barcelona
Year: 2017
Authors:

Yamamoto T., Shimoyama T., Umegae S.

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P498: Emerging role of the IL-33/ST2 axis in predicting mucosal response to anti-TNF therapy in ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Lopetuso L.R.*1,2, Petito V.3, Graziani C.3, Scannone D.4, Scaldaferri F.5, Pizarro T.T.6, Gasbarrini A.3

1Catholic University of the Sacread Hearth, Internal Medicine, Gastroenterology Division, Rome, Italy 2Case Western Reserve University, Pathology, Cleveland, United States 3Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy 4Catholic University of Sacred Heart, Pathology, Rome, Italy 5Catholic University of Sacred Heart, Internal Medicine and Gastroenterology, Rome, Italy 6Case Western Reserve University, Pathology, Cleveland, United States

P499: Sexual dysfunction is frequent among inflammatory bowel disease patients: results of a prospective studyECCO '17 Barcelona
Year: 2017
Authors:

Rivière P.*1, Zallot C.2, Desobry P.3, Sabaté J.-M.4, Vergniol J.1, Zerbib F.1, Peyrin-Biroulet L.2, Laharie D.1, Poullenot F.1

1Bordeaux University Hospital, Bordeaux, France 2Nancy University Hospital, Nancy, France 3Enedis GRDF, Lille, France 4Hôpital Louis-Mourier, Colombes, France

P500: Effectiveness and safety in Crohn's disease patients who were treated with CT-P13ECCO '17 Barcelona
Year: 2017
Authors:

Choe Y.H.*1, Lee S.-H.2, Park D.I.3, Lee J.H.4, Kim H.J.5, Kim Y.-H.6, Choi C.H.7, Eun C.S.8, Lee S.J.9, Lee S.9

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea 2Esoo Hospital, Digestive Endoscopic Center, Cheonan-si, South Korea 3Kangbuk Samsung Hospital, Department of Internal Medicine, Seoul, South Korea 4Seoul Song Do Colorectal Hospital, Department of Internal Medicine, Seoul, South Korea 5Kyung Hee University College of Medicine, Department of Internal Medicine, Seoul, South Korea 6Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, South Korea 7Chung-Ang University College of Medicine, Department of Internal Medicine, Seoul, South Korea 8Hanyang University Guri Hospital, Hanyang University College of Medicine, Department of Internal Medicine, Guri, South Korea 9CELLTRION, Inc., Incheon, South Korea

P501: Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)ECCO '17 Barcelona
Year: 2017
Authors:

Siegel C.A.*1, Lichtenstein G.2, Siegmund B.3, Lewis J.D.2, Wolf D.4, Louis E.5, Sebastian S.6, Hebuterne X.7, Bell A.8, Söderman C.9, Schubert S.10, Atreya R.11, Polyak S.12, Hoque S.13, Krummenerl A.14, Bokemeyer B.15, Krummenerl T.16, Shulmann S.17, Karlén P.18, Moum B.19, Dolin P.20

1Dartmouth-Hitchcock Medical Center, Departmnet of Gastroenterology, Lebanon, United States 2University of Pennsylvania Perelman School of Medicine, Division of Gastroenterology, Philadelphia, United States 3Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology, Berlin, Germany 4Atlanta Gastroenterology Associates, Atlanta, United States 5CHU Liège, Liège, Belgium 6Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom 7CHU Archet 2, Department of Gastroenterology, Nice, France 8Weston General Hospital, Weston Area Health Trust - Department of Gastroenterology, Weston Super Mare, United Kingdom 9Capio St Görans Hospital, Stockholm, Sweden 10Praxis für Gastroenterologie, Berlin, Germany 11University Hospital Erlangen, Department of Gastroenterology, Erlangen, Germany 12University of Iowa Health Care, Inflammatory Bowel Diseases & Celiac Disease Center, Iowa City, United States 13Barts Heath NHS Trust, Gastroenterology, London, United Kingdom 14Hospital Martha Maria Doelau, Halle, Germany 15Gastroenterologische Gemeinschaftspraxis Minden, Department of Gastroenterology, Minden, Germany 16Gastroenterologische Praxis am Germania-Campus, Münster, Germany 17Scott Shulman Medical, North Bay, Ontanio, Canada 18Danderyds Hospital, Department of Gastroenterology, Stockholm, Sweden 19Oslo University, Department of Gastroenterology, Oslo, Norway 20Takeda Development Centre Europe, Pharmacoepidemiology, London, United Kingdom

P502: Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatmentECCO '17 Barcelona
Year: 2017
Authors:

Zezos P.*1, Kabakchiev B.2, Weizman A.V.1, Nguyen G.C.1, Narula N.1, Croitoru K.1, Steinhart A.H.1, Silverberg M.S.1

1Mount Sinai Hospital, University of Toronto, Division of Gastroenterology, Toronto, Canada 2Mount Sinai Hospital, Samuel Lunenfeld Research Institute, Toronto, Canada

P503: Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practiceECCO '17 Barcelona
Year: 2017
Authors:

Ametzazurra A.1, Rivera N.2, Hernández A.M.1, Arreba M.P.3, Ruiz E.4, Ortíz J.3, Muñoz M.d.C.3, Torres N.1, Pascual J.1, Martínez A.1, Allande M.J.2, Nagore D.*1

1Progenika Biopharma SA, R&D Department, Derio, Spain 2Hospital de Basurto, Rheumatology, Research Unit, Bilbao, Spain 3Hospital de Basurto, Department of Gastroenterology, Bilbao, Spain 4Hospital de Basurto, Rheumatology, Bilbao, Spain

P504: Differences between paediatric and adult inflammatory bowel disease presentation – analysis based on the data from multicenter, prospective cohort observational study assessing safety of anti-TNF therapy – Satimos studyECCO '17 Barcelona
Year: 2017
Authors:

Sieczkowska-Golub J.*1, Jarzebicka D.1, Borys-Iwanicka A.2, Korlatowicz-Bilar A.3, Szaflarska-Popławska A.4, Grzybowska-Chlebowczyk U.5, Łazowska-Przeorek I.6, Daniluk U.7, Korczowski B.8, Sordyl B.9, Szczepanik M.10, Landowski P.11, Plocek A.12, Bąk-Drabik K.13, Zagorowicz E.14, Kierkus J.1

1The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland 2Independent Clinical Public Hospital No. 1, Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw, Poland 3Specialist Independent Public Health Care Centre for Children and Youth, Department of Pediatrics, Gastroenterology and Rheumatology, Szczecin, Poland 4University Hospital in Bydgoszcz, Department of Pediatrics, Allergology and Gastroenterology, Bydgoszcz, Poland 5The Independent Public Clinical Hospital no. 6 of the Medical University of Silesia in Katowice John Paul II Upper Silesian Child Health Centre, Department of Gastroenterology, Katowice, Poland 6Independent Public Children's Hospital in Warsaw, Department of Gastroenterology and Nutrition, Children, Warsaw, Poland 7University Hospital in Białystok, Department of Pediatrics, Gastroenterology and Allergology, Bialystok, Poland 8Regional Clinical Hospital No. 2, Department of Pediatric Gastroenterology, Rzeszow, Poland 9Polish Mother's Memorial Hospital Research Institute, Department of Gastroenterology, Allergy and Pediatrics, Lodz, Poland 10Clinical Hospital of Medical University in Poznan, Department of Gastroenterology and Metabolic Diseases, Poznan, Poland 11University Clinical Center - University Hospital, Department of Gastroenterology, Gdansk, Poland 12Central Hospital of Medical University in Lodz, Department of Allergology, Gastroenterology and Nutrition, Children, Lodz, Poland 13Independent Public Clinical Hospital No. 1 of Silesian Medical University in Katowice, Department of Pediatrics, Katowice, Poland 14Oncology Centre - Institute for them. Maria Sklodowska – Curie in Warsaw, Department of Gastroenterology Oncology, Warsaw, Poland

P505: Efficacy of MMX-mesalamine monotherapy for maintenance of remission in ulcerative colitis patients after mucosal healingECCO '17 Barcelona
Year: 2017
Authors:

Lopez-Diaz J., Ferreiro R., De la Iglesia D., Lorenzo A., Dominguez-Munoz J.E., Barreiro-de Acosta M.

University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain

P506: Psychological factors and quality of life in inflammatory bowel diseases patients: the Psycho studyECCO '17 Barcelona
Year: 2017
Authors:

Vegni E.1, Gilardi D.2, Corrò B.E.3, Menichetti J.4, Leone D.1, Allocca M.2, Bonovas S.5, Furfaro F.2, Danese S.2,6, Fiorino G.*7

1University of Milan, Department of Health Sciences, Milan, Italy 2Humanitas Research Hospital, IBD Center, Gastroenterology, Rozzano, Milan, Italy 3University of Milan, Milan, Italy 4Catholic University, Department of Psychology, Milan, Italy 5Humanitas Research Hospital, Department of Gastroenterology, IBD Center, Rozzano, Italy 6Humanitas University, Biomedical Sciences, Rozzano, Milan, Italy 7Humanitas Clinical and Research Center, IBD Center, Department of Gastroenterology, Rozzano, Italy

P507: Nutrition status in pre-surgical Crohn's disease, active Crohn's disease, Crohn's disease in remission and ulcerative colitis in remission: a cross-sectional studyECCO '17 Barcelona
Year: 2017
Authors:

Sandall A.M.*1, Patel K.V.2, O'Hanlon D.V.3, Smith S.J.1, Darakhshan A.A.4, Sanderson J.D.2, Lomer M.C.1,3

1King's College London, Diabetes and Nutritional Sciences Division, London, United Kingdom 2Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom 3Guy's and St Thomas' NHS Foundation Trust, Nutrition & Dietetics, London, United Kingdom 4Guy's and St Thomas' NHS Foundation Trust, Colorectal Surgery, London, United Kingdom

P508: Association between clinical outcome and post induction CT-P13 trough levels at week 14, in patients with inflammatory bowel disease. Preliminary results in an observational multicentric studyECCO '17 Barcelona
Year: 2017
Authors:

Elosua González A.*1, Oyόn Lara D.1, Nantes Castillejo Ó.1, Ogueta Fernández M.Ά.2, Gutiérrez Mendizábal P.3, Muñoz Villafranca M.C.3, Gόmez Irwin L.4, Muñagorri Santos A.I.5, Rodríguez Lago I.6, Rodríguez Gutiérrez C.1 IBD Study Group from the Basque-Navarre Society of Gastrointestinal Diseases

1Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain 2Hospital Universitario Araba, Gastroenterology, Vitoria, Spain 3Hospital Universitario Basurto, Gastroenterology, Bilbao, Spain 4Hospital Universitario Cruces, Gastroenterology, Barakaldo, Spain 5Hospital Universitario Donostia, Gastroenterology, San Sebastián, Spain 6Hospital Galdakao-Usansolo, Gastroenterology, Usansolo, Spain

P509: IBD cancer and serious infections in Europe (I-CARE): a European prospective observational studyECCO '17 Barcelona
Year: 2017
Authors:

The I-CARE Study Group

P510: Assessment of study group – patients with inflammatory bowel disease, treated with monoclonal anti-TNF alpha: a multicenter, prospective cohort observational study, Satimos – preliminary report in pediatric populationECCO '17 Barcelona
Year: 2017
Authors:

Jarzebicka D.*1, Sieczkowska J.1, Borys-Iwanicka A.2, Korlatowicz-Bilar A.3, Szaflarska-Popławska A.4, Grzybowska-Chlebowczyk U.5, Łazowska-Przeorek I.6, Daniluk U.7, Korczowski B.8, Sordyl B.9, Szczepanik M.10, Landowski P.11, Plocek A.12, Bąk-Drabik K.13, Zagόrowicz E.14, Kierkus J.1

1The Children's Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland 2Independent Clinical Public Hospital No. 1, Department of Pediatrics, Gastroenterology and Nutrition, Wrocław, Poland 3Specialist Independent Public Health Care Centre for Children and Youth, Department of Pediatrics, Gastroenterology and Rheumatology, Szczecin, Poland 4University Hospital, Department of Pediatrics, Allergology and Gastroenterology, Bydgoszcz, Poland 5The Independent Public Clinical Hospital no. 6 of the Medical University of Silesia in Katowice John Paul II Upper Silesian Child Health Centre, w Katowicach Gόrnośląskie Centrum Zdrowia Dziecka im. Jana Pawła II Department of Gastroenterology, Katowice, Poland 6Independent Public Children's Hospital, Department of Gastroenterology and Nutrition, Children, Warsaw, Poland 7University Hospital, Department of Pediatrics, Gastroenterology and Allergology, Białystok, Poland 8Regional Clinical Hospital No. 2, Department of Pediatric Gastroenterology, Rzeszόw, Poland 9Polish Mother's Memorial Hospital Research Institute, Department of Gastroenterology, Allergy and Pediatrics, Łόdź, Poland 10Clinical Hospital of Medical University, Department of Gastroenterology and Metabolic Diseases, Poznań, Poland 11University Clinical Center - University Hospital, Department of Gastroenterology, Gdańsk, Poland 12Central Hospital of Medical University, Department of Allergology, Gastroenterology and Nutrition, Children, Łόdź, Poland 13Independent Public Clinical Hospital No. 1 of Silesian Medical University, Department of Pediatric, Zabrze, Poland 14Oncology Centre - Institute for them. Maria Skłodowska – Curie, Department of Gastroenterology Oncology, Warsaw, Poland

P511: Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01)ECCO '17 Barcelona
Year: 2017
Authors:

Wolf D.*1, Lewis J.D.2, Siegmund B.3, Lichtenstein G.2, Sebastian S.4, Siegel C.A.5, Louis E.6, Haas T.7, Nedd K.8, Subramanian S.9, Aguilar H.10, Egan L.11, Gasche C.12, Doherty G.13, Lobo A.14, Spearman D.15, Patel A.16, Moparty R.17, Brookes M.18, Hebuterne X.19, Moum B.20, Dolin P.21

1Atlanta Gastroenterology Associates, Atlanta, United States 2University of Pennsylvania Perelman School of Medicine, Division of Gastroenterology, Philadelphia, United States 3Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology, Berlin, Germany 4Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom 5Dartmouth-Hitchcock Medical Center, Departmnet of Gastroenterology, Lebanon, United States 6CHU Liège, Liège, Belgium 7Darm Praxis Salzburg, Salzburg, Austria 8Infusion Associates, Grand Rapids, United States 9Royal Liverpool University Teaching Hospital, Department of Gastroenterology, Liverpool, United Kingdom 10Shreveport Endoscopy Center, Shreveport, LA, United States 11NUI Galway, Department of Gastroenterology, Galway, Ireland 12Medical University of Vienna, Wien, Austria 13St Vincent's University Hospital, Center for Colorectal Disease, Dublin, Ireland 14Sheffield Teaching Hospitals NHS Foundation Trust, Department of Gastroenterology, Sheffield, United Kingdom 15San Antonio Military Medical Center, San Antonio, TX, United States 16Medical College of Wisconsin, Milwaukee, United States 17Spring Gastroenterology, Humble, TX, United States 18The Royal Wolverhampton Hospital NHS, New Cross Hospital, Department of Gastroenterology, Wolverhampton, United Kingdom 19CHU Archet 2, Department of Gastroenterology, Nice, France 20Oslo University, Department of Gastroenterology, Oslo, Norway 21Takeda Development Centre Europe, Pharmacoepidemiology, London, United Kingdom

P512: Real world use of adalimumab: effects on corticosteroid treatment and hospital resource utilisation in UK patients with moderate/severe ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Watts G.*1, Arasaradnam R.2, Travis S.3, Sharma A.4, Awasthi A.5, Limdi J.6, Bishop-Bailey A.7, Mclain-Smith S.7, Finney-Hayward T.8

1University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom 2University Hospitals Coventry & Warwick NHS Trust, Coventry & Warwick, United Kingdom 3Oxford University Hospitals NHS Trust, Oxford, United Kingdom 4Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, United Kingdom 5Walsall Healthcare NHS Trust, Walsall, United Kingdom 6The Pennine Acute Hospitals NHS Trust, Crumpsall, United Kingdom 7pH Associates, Marlow, United Kingdom 8AbbVie, UK, Maidenhead, United Kingdom

P513: Managing IBD patients on adalimumab based on trough levels and antibodiesECCO '17 Barcelona
Year: 2017
Authors:

Parisi I., Atherton R., McCartney S., Vega R., Mehta S., Whitley L., Kabir M., Kiparissi F., Bloom S.

University College London Hospital, Department of Gastroenterology, London, United Kingdom

P514: Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety dataECCO '17 Barcelona
Year: 2017
Authors:

Buer L.*1,2, Høivik M.L.1, Medhus A.W.1, Moum B.1,2

1Oslo University Hospital, Department of Gastroenterology, Oslo, Norway 2University of Oslo, Institute of Clinical Medicine, Oslo, Norway